STM Journals Peer-reviewed research from Consortium e-Learning Network

Research and Reviews : A Journal of Biotechnology Review Article

Breakthroughs in Biotechnology for the Regulation of Infectious Diseases

  1. Tanujaa S.R Department of Biotechnology, Karunya Institute of Science of Technology, Coimbatore

Abstract

Infectious diseases have a heavy impact on both public health and the world’s economies. In most diseases, antibiotic resistance has become widespread over time. A variety of diseases comprising pneumonia, tuberculosis, and gonorrhea go through the same evolutionary processes, which include the formation of drug-resistant pathogens in response to selection pressure from medications and their potential extinction when drug use is ceased. Since the occurrence of drug resistance in serious infections typically coincides with poverty, drug-resistant illnesses including Mycobacterium tuberculosis, and Neisseria gonorrhea pose a threat to widening health disparities worldwide. This affects healthcare significantly and seriously jeopardizes many of the breakthroughs in clinical medicine made in the 20th century, even in settings with ample resources. New tactics and technological platforms inclusive of genomics, proteomics, transcriptomics, nanotechnology, and bioinformatics approaches are desperately needed to address these threats and obstacles. The field of biotechnology and its many applications are crucial in addressing this problem. This study will concentrate on the most recent biotechnological developments, such as the use of Monoclonal antibodies, CRISPR-Cas Technology 3D Bioprinting, and more to address the problem of drug resistance and the difficulties encountered in effective commercialization.

Keywords

References (120)

  1. Founou LL, Founou RC, Essack SY. Antibiotic resistance in the food chain: A developing country-perspective. Frontiers in microbiology. 2016;7:1881.
  2. Jindal AK, Pandya K, Khan ID. Antimicrobial resistance: A public health challenge. Medical Journal Armed Forces India. 2015;71(2):178-181. doi:10.1016/j.mjafi.2014.04.011
  3. van Doorn HR. The epidemiology of emerging infectious diseases and pandemics. Medicine. 2021;49(10):659-662. doi:10.1016/j.mpmed.2021.07.011
  4. Nathwani D, Varghese D, Stephens J, Ansari W, Martin S, Charbonneau C. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrobial Resistance & Infection Control. 2019;8(1). doi:10.1186/s13756-019-0471-0
  5. Fekadu G, Yao J, You JHS. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis. PLOS ONE. 2022;17(8):e0272770. doi:10.1371/journal.pone.0272770
  6. Saleem Z, Hassali MA, Godman B, Versporten A, Hashmi FK, Saeed H, et al. Point prevalence surveys of antimicrobial use: a systematic review and the implications. Expert Review of Anti-infective Therapy. 2020;18(9):897-910. doi:10.1080/14787210.2020.1767593
  7. Jamrozik E, Selgelid M. Ethics and drug resistance: Collective responsibility for global public health. Cham: Springer International Publishing; 2020.
  8. Silva-Santana G, Silva CMF, Olivella JGB, Silva IF, Fernandes LMO, Sued-Karam BR, et al. Worldwide survey of Corynebacterium striatum increasingly associated with human invasive infections, nosocomial outbreak, and antimicrobial multidrug-resistance, 1976–2020. Archives of Microbiology. 2021;203(5):1863-1880. doi:10.1007/s00203-021-02246-1
  9. Rudrapal M, Paudel KR, Pangeni R. Editorial: Drug repurposing and polypharmacology: A synergistic approach in multi-target based drug discovery. Frontiers in Pharmacology. 2022;13. doi:10.3389/fphar.2022.1101007
  10. Sautter RL, Halstead DC. Need of the Hour: Addressing the Challenges of Multi-Drug-Resistant Health Care-Associated Infections and the Role of the Laboratory in Lowering Infection Rates. Clinical Microbiology Newsletter. 2018;40(2):11-16. doi:10.1016/j.clinmicnews.2018.01.001
  11. Olaru ID, Tacconelli E, Yeung S, Ferrand RA, Stabler RA, Hopkins H, et al. The association between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2021;27(6):846-853. doi:10.1016/j.cmi.2021.03.026
  12. Connor BA, Dawood R, Riddle MS, Hamer DH. Cholera in travellers: a systematic review. Journal of Travel Medicine. 2019;26(8). doi:10.1093/jtm/taz085
  13. Singhai M, Dhar Shah Y, Gupta N, Bala M, Kulsange S, Kataria J, et al. Chronicle down memory lane: India's sixty years of plague experience. Indian Journal of Medical Microbiology. 2021;39(3):279-285. doi:10.1016/j.ijmmb.2021.06.007
  14. Nicastri E, Kobinger G, Vairo F, Montaldo C, Mboera LEG, Ansunama R, et al. Ebola Virus Disease. Infectious Disease Clinics of North America. 2019;33(4):953-976. doi:10.1016/j.idc.2019.08.005
  15. Zheng R, Wang Q, Wu R, Paradkar PN, Hoffmann AA, Wang GH. Holobiont perspectives on tripartite interactions among microbiota, mosquitoes, and pathogens. The ISME Journal. 2023;17(8):1143-1152. doi:10.1038/s41396-023-01436-7
  16. Zheng W, Sun W, Simeonov A. Drug repurposing screens and synergistic drug‐combinations for infectious diseases. British Journal of Pharmacology. 2017;175(2):181-191. doi:10.1111/bph.13895
  17. Howard DH, Scott RD, Packard R, Jones D. The Global Impact of Drug Resistance. Clinical Infectious Diseases. 2003;36(Supplement_1):S4-S10. doi:10.1086/344656
  18. Snowden FM. Emerging and reemerging diseases: a historical perspective. Immunological Reviews. 2008;225(1):9-26. doi:10.1111/j.1600-065x.2008.00677.x
  19. Morens DM, Fauci AS. Emerging Infectious Diseases: Threats to Human Health and Global Stability. PLoS Pathogens. 2013;9(7):e1003467. doi:10.1371/journal.ppat.1003467
  20. Joy M, Krishnaveni M. A review of epidemic surveillance systems for infectious diseases. In: 2022 International Conference on Computing, Communication, Security and Intelligent Systems (IC3SIS). IEEE; 2022.
  21. Choi J, Cho Y, Shim E, Woo H. Web-based infectious disease surveillance systems and public health perspectives: a systematic review. BMC Public Health. 2016;16(1). doi:10.1186/s12889-016-3893-0
  22. Carrion M, Madoff LC. ProMED-mail: 22 years of digital surveillance of emerging infectious diseases. International Health. 2017;9(3):177-183. doi:10.1093/inthealth/ihx014
  23. Gu Y, Zhang T, Chen H, Wang F, Pu Y, Gao C, et al. Mini Review on Flexible and Wearable Electronics for Monitoring Human Health Information. Nanoscale Research Letters. 2019;14(1). doi:10.1186/s11671-019-3084-x
  24. Burnham JP, Olsen MA, Stwalley D, Kwon JH, Babcock HM, Kollef MH. Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections. Open Forum Infectious Diseases. 2018;5(3). doi:10.1093/ofid/ofy026
  25. O'Brien TF. Emergence, Spread, and Environmental Effect of Antimicrobial Resistance: How Use of an Antimicrobial Anywhere Can Increase Resistance to Any Antimicrobial Anywhere Else. Clinical Infectious Diseases. 2002;34(s3):S78-S84. doi:10.1086/340244
  26. King DA, Peckham C, Waage JK, Brownlie J, Woolhouse MEJ. Infectious Diseases: Preparing for the Future. Science. 2006;313(5792):1392-1393. doi:10.1126/science.1129134
  27. Maddah N, Verma A, Almashmoum M, Ainsworth J. Effectiveness of Public Health Digital Surveillance Systems for Infectious Disease Prevention and Control at Mass Gatherings: Systematic Review. Journal of Medical Internet Research. 2023;25:e44649. doi:10.2196/44649
  28. Sun G, Trung NV, Hoi LT, Hiep PT, Ishibashi K, Matsui T. Visualisation of epidemiological map using an Internet of Things infectious disease surveillance platform. Critical Care. 2020;24(1). doi:10.1186/s13054-020-03132-w
  29. Kang WT, Xu H, Liao Y, Guo Q, Huang Q, Xu Y, et al. Qualitative and Quantitative Detection of Multiple Sexually Transmitted Infection Pathogens Reveals Distinct Associations with Cervicitis and Vaginitis. Microbiology Spectrum. 2022;10(6). doi:10.1128/spectrum.01966-22
  30. Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, et al. Sexually transmitted infections: challenges ahead. The Lancet Infectious Diseases. 2017;17(8):e235-e279. doi:10.1016/s1473-3099(17)30310-9
  31. Unemo M, Golparian D, Shafer WM. Challenges with gonorrhea in the era of multi-drug and extensively drug resistance – are we on the right track? Expert Review of Anti-infective Therapy. 2014;12(6):653-656. doi:10.1586/14787210.2014.906902
  32. Centers for Disease Control and Prevention. Basic information about ARG - STD information from CDC. CDC. Available at https://www.cdc.gov/std/gonorrhea/drug-resistant/basic.htm [Accessed on October, 2023].
  33. Rice PA, Shafer WM, Ram S, Jerse AE. Neisseria gonorrhoeae: Drug Resistance, Mouse Models, and Vaccine Development. Annual Review of Microbiology. 2017;71(1):665-686. doi:10.1146/annurev-micro-090816-093530
  34. Unemo M, Nicholas RA. Emergence of Multidrug-Resistant, Extensively Drug-Resistant and Untreatable Gonorrhea. Future Microbiology. 2012;7(12):1401-1422. doi:10.2217/fmb.12.117
  35. Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, et al. Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub–Saharan Africa. The Journal of Infectious Diseases. 2017;215(9):1362-1365. doi:10.1093/infdis/jix089
  36. Chinnambedu RS, Marimuthu RR, Sunil SS, Amrose P, Ramachandran V, Pachamuthu B. Changing antibiotic resistance profile of Staphylococcus aureus isolated from HIV patients (2012–2017) in Southern India. Journal of Infection and Public Health. 2020;13(1):75-79. doi:10.1016/j.jiph.2019.06.015
  37. Donkor ES, Kotey FCN, Dayie NTKD, Duodu S, Tetteh-Quarcoo PB, Osei MM, et al. Colonization of HIV-Infected Children with Methicillin-Resistant Staphylococcus aureus. Pathogens. 2019;8(1):35. doi:10.3390/pathogens8010035
  38. Soroka M, Wasowicz B, Rymaszewska A. Loop-Mediated Isothermal Amplification (LAMP): The Better Sibling of PCR? Cells. 2021;10(8):1931. doi:10.3390/cells10081931
  39. ResearchGate. A critical review on PCR, its types, and applications. Available at https://www.researchgate.net/publication/266971527_a_critical_review_on_PCR_its_types_and_applications [Accessed on October, 2023].
  40. Parashar D, Chauhan DS, Sharma VD, Katoch VM. Applications of real-time PCR technology to mycobacterial research. Indian J Med Res. 2006;124.
  41. Rajalakshmi S. Different types of PCR techniques and their applications. Available at https://faculty.ksu.edu.sa/sites/default/files/different_types_of_pcr_techniques_and_its_applications.pdf [Accessed on October, 2023].
  42. Elnifro EM, Ashshi AM, Cooper RJ, Klapper PE. Multiplex PCR: Optimization and application in diagnostic virology. Clin Microbiol Rev. 2000;13(4):559. doi:10.1128/cmr.13.4.559-570.2000.
  43. Green MR, Sambrook J. Inverse Polymerase Chain Reaction (PCR). Cold Spring Harbor Protocols. 2019;2019(2):pdb.prot095166. doi:10.1101/pdb.prot095166
  44. Karunasagar I. Bacteria: Vibrio vulnificus. In: Encyclopedia of Food Safety. Elsevier; 2014. pp. 564–569.
  45. Olsson M, Strålin K, Holmberg H. Clinical significance of nested polymerase chain reaction and immunofluorescence for detection of Pneumocystis carinii pneumonia. Clinical Microbiology and Infection. 2001;7(9):492-497. doi:10.1046/j.1469-0691.2001.00309.x
  46. Bièche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem. 1999;45:1148–1156.
  47. Scanlon KJ, Kashani‐Sabet M. Utility of the polymerase chain reaction in detection of gene expression in drug‐resistant human tumors. Journal of Clinical Laboratory Analysis. 1989;3(5):323-329. doi:10.1002/jcla.1860030512
  48. Cason C, D’Accolti M, Soffritti I, Mazzacane S, Comar M, Caselli E. Next-generation sequencing and PCR technologies in monitoring the hospital microbiome and its drug resistance. Frontiers in Microbiology. 2022;13. doi:10.3389/fmicb.2022.969863
  49. Kouamou V, Ndhlovu CE, Katzenstein D, Manasa J. Rapid HIV-1 drug resistance testing in a resource-limited setting: The Pan Degenerate Amplification and Adaptation assay (PANDAA). Pan Afr Med J. 2021;40. doi:10.11604/pamj.2021.40.57.28558.
  50. The Pan Degenerate Amplification and Adaptation (PANDAA) assay: a solution for HIV-1 drug resistance testing in a resource limited setting? Journal of Allergy & Infectious Diseases. 2021;2(2). doi:10.46439/allergy.2.020
  51. Denaro M, Ghandour H, Long JE, et al. Validation of PANDAA qDx HIVDR RTI: a simple and scalable real-time PCR-based HIV drug resistance genotyping kit for the management of NNRTI-based ART failure. Available at https://programme.ias2019.org/PAGMaterial/eposters/2172.pdf [Accessed on October, 2023].
  52. Schmitt S, Stephan R, Huebschke E, Schaefle D, Merz A, Johler S. DNA microarray-based characterization and antimicrobial resistance phenotypes of clinical MRSA strains from animal hosts. Journal of Veterinary Science. 2020;21(4). doi:10.4142/jvs.2020.21.e54
  53. Protonotariou E, Meletis G, Papadopoulou D, Kachrimanidou M, Toptsi L, Skoura L. Evaluation of the “AMR Direct Flow Chip Kit” DNA microarray for detecting antimicrobial resistance genes directly from rectal and nasopharyngeal clinical samples upon ICU admission. Enfermedades infecciosas y microbiologia clinica (English ed.). 2021;39(6):276-278. doi:10.1016/j.eimce.2020.05.014
  54. Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nature Medicine. 1998;4(11):1293-1301. doi:10.1038/3282
  55. Hughes TR, Roberts CJ, Dai H, Jones AR, Meyer MR, Slade D, et al. Widespread aneuploidy revealed by DNA microarray expression profiling. Nature Genetics. 2000;25(3):333-337. doi:10.1038/77116
  56. More M, Gutiérrez G, Rothschild M, Bertolini F, Ponce de León FA. Evaluation of SNP Genotyping in Alpacas Using the Bovine HD Genotyping Beadchip. Frontiers in Genetics. 2019;10. doi:10.3389/fgene.2019.00361
  57. Onogi A, Watanabe T, Ogino A, Kurogi K, Togashi K. Genomic prediction with non-additive effects in beef cattle: stability of variance component and genetic effect estimates against population size. BMC Genomics. 2021;22(1). doi:10.1186/s12864-021-07792-y
  58. Jenkins CA, Dog Biomedical Variant Database Consortium, Schofield EC, Mellersh CS, De Risio L, Ricketts SL. Improving the resolution of canine genome‐wide association studies using genotype imputation: A study of two breeds. Animal Genetics. 2021;52(5):703-713. doi:10.1111/age.13117
  59. Single nucleotide polymorphisms in Bison bison identified by the GGP Bovine 50K SNP assay. Available at https://buscaintegrada.ufrj.br/Record/oai:doaj.org-article:dfb8a45b920246c6a0316
  60. fb5b88d8b52 [Accessed on October, 2023].
  61. Ferraz JBS, Wu XL, Li H, Xu J, Ferretti R, Simpson B, et al. Development and evaluation of a low-density single-nucleotide polymorphism chip specific to Bos indicus cattle. Animal Production Science. 2020;60(15):1769-1776. doi:10.1071/an19396
  62. Gras MA, Grosu H. Informational steps and tools in genomic selection of livestock: A review. Available at https://ibna.ro/arhiva/08-AZ-156-Mihail_Gras_28-02-2020.pdf [Accessed on October, 2023].
  63. Chartrand C, Leeflang MMG, Minion J, Brewer T, Pai M. Accuracy of Rapid Influenza Diagnostic Tests. Annals of Internal Medicine. 2012;156(7):500-511. doi:10.7326/0003-4819-156-7-201204030-00403
  64. Kim H, Kang H, Kim HN, Kim H, Moon J, Guk K, et al. Development of 6E3 antibody-mediated SERS immunoassay for drug-resistant influenza virus. Biosensors and Bioelectronics. 2021;187:113324. doi:10.1016/j.bios.2021.113324
  65. Yi Z, Xu X, Meng X, Liu C, Zhou Q, Gong D, et al. Emerging markers for antimicrobial resistance monitoring. Chinese Chemical Letters. 2023;34(10):108238. doi:10.1016/j.cclet.2023.108238
  66. Lee WS, Lee S, Kang T, Ryu CM, Jeong J. Detection of Ampicillin-Resistant E. coli Using Novel Nanoprobe-Combined Fluorescence In Situ Hybridization. Nanomaterials. 2019;9(5):750. doi:10.3390/nano9050750
  67. Dillon L, Dimonaco NJ, Creevey CJ. O04 Understanding the key role of accessory genes in AMR phenotype through interpretable machine learning techniques. JAC-Antimicrobial Resistance. 2023;5(Supplement_2). doi:10.1093/jacamr/dlad066.004
  68. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, et al. Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. Antimicrobial Agents and Chemotherapy. 2019;63(11). doi:10.1128/aac.00483-19
  69. Hendriksen RS, Bortolaia V, Tate H, Tyson GH, Aarestrup FM, McDermott PF. Using Genomics to Track Global Antimicrobial Resistance. Frontiers in Public Health. 2019;7. doi:10.3389/fpubh.2019.00242
  70. Peng B, Li H, Peng X. Proteomics approach to understand bacterial antibiotic resistance strategies. Expert Review of Proteomics. 2019;16(10):829-839. doi:10.1080/14789450.2019.1681978
  71. Staub I, Sieber SA. β-Lactam Probes As Selective Chemical-Proteomic Tools for the Identification and Functional Characterization of Resistance Associated Enzymes in MRSA. Journal of the American Chemical Society. 2009;131(17):6271-6276. doi:10.1021/ja901304n
  72. Horgan RP, Kenny LC. ‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics. The Obstetrician & Gynaecologist. 2011;13(3):189-195. doi:10.1576/toag.13.3.189.27672
  73. Cabral-Marques O, Schimke LF, de Oliveira EB, El Khawanky N, Ramos RN, Al-Ramadi BK, et al. Flow Cytometry Contributions for the Diagnosis and Immunopathological Characterization of Primary Immunodeficiency Diseases With Immune Dysregulation. Frontiers in Immunology. 2019;10. doi:10.3389/fimmu.2019.02742
  74. Ndagi U, Falaki AA, Abdullahi M, Lawal MM, Soliman ME. Antibiotic resistance: bioinformatics-based understanding as a functional strategy for drug design. RSC Advances. 2020;10(31):18451-18468. doi:10.1039/d0ra01484b
  75. Kavvas ES, Yang L, Monk JM, Heckmann D, Palsson BO. A biochemically-interpretable machine learning classifier for microbial GWAS. Nature Communications. 2020;11(1). doi:10.1038/s41467-020-16310-9
  76. Melo MCR, Maasch JRMA, de la Fuente-Nunez C. Accelerating antibiotic discovery through artificial intelligence. Communications Biology. 2021;4(1). doi:10.1038/s42003-021-02586-0
  77. Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA, et al. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. Microbial Genomics. 2017;3(10). doi:10.1099/mgen.0.000131
  78. Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, et al. Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. Antimicrobial Agents and Chemotherapy. 2019;63(11). doi:10.1128/aac.00483-19
  79. Crossette E, Gumm J, Langenfeld K, Raskin L, Duhaime M, Wigginton K. Metagenomic Quantification of Genes with Internal Standards. mBio. 2021;12(1). doi:10.1128/mbio.03173-20
  80. Arango-Argoty G, Garner E, Pruden A, Heath LS, Vikesland P, Zhang L. DeepARG: a deep learning approach for predicting antibiotic resistance genes from metagenomic data. Microbiome. 2018;6(1). doi:10.1186/s40168-018-0401-z
  81. Zankari E, Allesøe R, Joensen KG, Cavaco LM, Lund O, Aarestrup FM. PointFinder: a novel web tool for WGS-based detection of antimicrobial resistance associated with chromosomal point mutations in bacterial pathogens. Journal of Antimicrobial Chemotherapy. 2017;72(10):2764-2768. doi:10.1093/jac/dkx217
  82. Zhang F, Wang M, Xi J, Yang J, Li A. A novel heterogeneous network-based method for drug response prediction in cancer cell lines. Scientific Reports. 2018;8(1). doi:10.1038/s41598-018-21622-4
  83. Qi R, Zou Q. Trends and Potential of Machine Learning and Deep Learning in Drug Study at Single-Cell Level. Research. 2023;6. doi:10.34133/research.0050
  84. Berglund F, Österlund T, Boulund F, Marathe NP, Larsson DGJ, Kristiansson E. Identification and reconstruction of novel antibiotic resistance genes from metagenomes. Microbiome. 2019;7(1). doi:10.1186/s40168-019-0670-1
  85. Marini S, Boucher C, Noyes N, Prosperi M. The K-mer antibiotic resistance gene variant analyzer (KARGVA). Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1060891
  86. Lakin SM, Kuhnle A, Alipanahi B, Noyes NR, Dean C, Muggli M, et al. Hierarchical Hidden Markov models enable accurate and diverse detection of antimicrobial resistance sequences. Communications Biology. 2019;2(1). doi:10.1038/s42003-019-0545-9
  87. Doster E, Lakin SM, Dean CJ, Wolfe C, Young JG, Boucher C, et al. MEGARes 2.0: a database for classification of antimicrobial drug, biocide and metal resistance determinants in metagenomic sequence data. Nucleic Acids Research. 2019;48(D1):D561-D569. doi:10.1093/nar/gkz1010
  88. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, et al. ResFinder 4.0 for predictions of phenotypes from genotypes. Journal of Antimicrobial Chemotherapy. 2020;75(12):3491-3500. doi:10.1093/jac/dkaa345
  89. De R. Metagenomics: aid to combat antimicrobial resistance in diarrhea. Gut Pathogens. 2019;11(1). doi:10.1186/s13099-019-0331-8
  90. Sahu T, Ratre YK, Chauhan S, Bhaskar LVKS, Nair MP, Verma HK. Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. Journal of Drug Delivery Science and Technology. 2021;63:102487. doi:10.1016/j.jddst.2021.102487
  91. Blecher K, Nasir A, Friedman A. The growing role of nanotechnology in combating infectious disease. Virulence. 2011;2(5):395-401. doi:10.4161/viru.2.5.17035
  92. Jain S, Nehra M, Kumar R, Dilbaghi N, Hu T, Kumar S, et al. Internet of medical things (IoMT)-integrated biosensors for point-of-care testing of infectious diseases. Biosens Bioelectron. 2021;179:113074. doi:1 0.1016/j.bios.2021.113074.
  93. Dubey AK, Kumar Gupta V, Kujawska M, Orive G, Kim NY, Li CZ, et al. Exploring nano-enabled CRISPR-Cas-powered strategies for efficient diagnostics and treatment of infectious diseases. Journal of Nanostructure in Chemistry. 2022;12(5):833-864. doi:10.1007/s40097-022-00472-7
  94. Ahmed S, Ning J, Peng D, Chen T, Ahmad I, Ali A, et al. Current advances in immunoassays for the detection of antibiotics residues: a review. Food and Agricultural Immunology. 2020;31(1):268-290. doi:10.1080/09540105.2019.1707171
  95. Ni Y, Rosier BJHM, van Aalen EA, Hanckmann ETL, Biewenga L, Pistikou AMM, et al. A plug-and-play platform of ratiometric bioluminescent sensors for homogeneous immunoassays. Nature Communications. 2021;12(1). doi:10.1038/s41467-021-24874-3
  96. Sulovari A, Ninomiya MJ, Beck CA, Ricciardi BF, Ketonis C, Mesfin A, et al. Clinical utilization of species‐specific immunoassays for identification of Staphylococcus aureus and Streptococcus agalactiae in orthopedic infections. Journal of Orthopaedic Research. 2020;39(10):2141-2150. doi:10.1002/jor.24935
  97. Haddad NS, Nozick S, Kim G, Ohanian S, Kraft C, Rebolledo PA, et al. Novel immunoassay for diagnosis of ongoing Clostridioides difficile infections using serum and medium enriched for newly synthesized antibodies (MENSA). Journal of Immunological Methods. 2021;492:112932. doi:10.1016/j.jim.2020.112932
  98. Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine. 2009;27:G38-G46. doi:10.1016/j.vaccine.2009.09.105
  99. Thakare, R., Dasgupta, A., Chopra, S. Bezlotoxumab for the treatment of Clostridium difficile-associated diarrhea. Drugs of Today. 2017;53(7):385. doi:10.1358/dot.2017.53.7.2655240
  100. Yamamoto BJ, Shadiack AM, Carpenter S, Sanford D, Henning LN, Gonzales N, et al. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax. Antimicrobial Agents and Chemotherapy. 2016;60(10):5796-5805. doi:10.1128/aac.01102-16
  101. Farahnik B, Beroukhim K, Zhu TH, Abrouk M, Nakamura M, Singh R, et al. Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatology and Therapy. 2016;6(1):25-37. doi:10.1007/s13555-016-0102-0
  102. Blair HA. Emicizumab: A Review in Haemophilia A. Drugs. 2019;79(15):1697-1707. doi:10.1007/s40265-019-01200-2
  103. Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. New England Journal of Medicine. 2017;376(4):305-317. doi:10.1056/nejmoa1602615
  104. Beccari MV, Mogle BT, Sidman EF, Mastro KA, Asiago-Reddy E, Kufel WD. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Antimicrobial Agents and Chemotherapy. 2019;63(6). doi:10.1128/aac.00110-19
  105. Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opinion on Biological Therapy. 2011;11(11):1455-1467. doi:10.1517/14712598.2011.608062
  106. Shivalingaiah AH, Shankaraiah RH, Hanumanthaiah AND. Safety of new indigenous human Rabies Monoclonal Antibody (RMAb) for Post Exposure Prophylaxis. Indian Journal of Community Health. 2018;30(3):196-201. doi:10.47203/ijch.2018.v30i03.004
  107. Mueller SM, Itin P, Haeusermann P. Muckle-Wells Syndrome Effectively Treated with Canakinumab: Is the Recommended Dosing Schedule Mandatory? Dermatology. 2011;223(2):113-118. doi:10.1159/000331580
  108. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011;377(9767):721-731. doi:10.1016/s0140-6736(10)61354-2
  109. Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, et al. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine. 2019;380(4):335-346. doi:10.1056/nejmoa1806311
  110. Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, et al. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. Journal of Crohn's and Colitis. 2016:jjw177. doi:10.1093/ecco-jcc/jjw177
  111. Munguia J, Nizet V. Pharmacological Targeting of the Host–Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs. Trends in Pharmacological Sciences. 2017;38(5):473-488. doi:10.1016/j.tips.2017.02.003
  112. Ramamurthy D, Nundalall T, Cingo S, Mungra N, Karaan M, Naran K, et al. Recent advances in immunotherapies against infectious diseases. Immunotherapy Advances. 2020;1(1). doi:10.1093/immadv/ltaa007
  113. Junaid M, Thirapanmethee K, Khuntayaporn P, Chomnawang MT. CRISPR-based gene editing in Acinetobacter baumannii to combat antimicrobial resistance. Pharmaceuticals (Basel). 2023;16:920. doi:10.3390/ph160709.
  114. Hille F, Charpentier E. CRISPR-Cas: biology, mechanisms and relevance. Philosophical Transactions of the Royal Society B: Biological Sciences. 2016;371(1707):20150496. doi:10.1098/rstb.2015.0496
  115. Uthayakumar D, Sharma J, Wensing L, Shapiro RS. CRISPR-Based Genetic Manipulation of Candida Species: Historical Perspectives and Current Approaches. Frontiers in Genome Editing. 2021;2. doi:10.3389/fgeed.2020.606281
  116. Stocco G, Lucafò M, Decorti G. Pharmacogenomics of Antibiotics. International Journal of Molecular Sciences. 2020;21(17):5975. doi:10.3390/ijms21175975
  117. Dlozi PN, Gladchuk A, Crutchley RD, Keuler N, Coetzee R, Dube A. Cathelicidins and defensins antimicrobial host defense peptides in the treatment of TB and HIV: Pharmacogenomic and nanomedicine approaches towards improved therapeutic outcomes. Biomedicine & Pharmacotherapy. 2022;151:113189. doi:10.1016/j.biopha.2022.113189
  118. Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. Journal of Controlled Release. 2015;217:308-314. doi:10.1016/j.jconrel.2015.09.028
  119. Varghese R, Sood P, Salvi S, Karsiya J, Kumar D. 3D printing in the pharmaceutical sector: Advances and evidences. Sensors International. 2022;3:100177. doi:10.1016/j.sintl.2022.100177
  120. Qureshi A, Niazi JH. Biosensors for detecting viral and bacterial infections using host biomarkers: a review. The Analyst. 2020;145(24):7825-7848. doi:10.1039/d0an00896f
Support